- Home
- BANC vs DNLI Comparison
BANC vs DNLI Comparison
Compare BANC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANC | DNLI |
|---|---|---|
| Founded | 1941 | 2013 |
| Country | United States | United States |
| Employees | 1904 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BANC | DNLI |
|---|---|---|
| Price | $18.92 | $19.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $20.85 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.93 | N/A |
| Revenue Next Year | $8.03 | $408.85 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.19 | $12.58 |
| 52 Week High | $21.61 | $23.77 |
Technical Indicators
Market Signals| Indicator | BANC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 49.30 |
| Support Level | $16.30 | $18.86 |
| Resistance Level | $21.43 | $20.71 |
| Average True Range (ATR) | 0.45 | 0.85 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 73.93 | 35.74 |
Price Performance
Historical ComparisonAbout BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.